Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…